These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36336829)

  • 1. Parallel imports under a manufacturer rebate and a price freeze: Evidence from Germany.
    Birg L
    Health Econ; 2023 Feb; 32(2):302-323. PubMed ID: 36336829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel trade of pharmaceuticals: The Danish market for statins.
    Méndez SJ
    Health Econ; 2018 Feb; 27(2):333-356. PubMed ID: 28868645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The welfare impact of parallel imports: a structural approach applied to the German market for oral anti-diabetics.
    Duso T; Herr A; Suppliet M
    Health Econ; 2014 Sep; 23(9):1036-57. PubMed ID: 25139795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pricing and welfare implications of parallel imports in the pharmaceutical industry.
    Jelovac I; Bordoy C
    Int J Health Care Finance Econ; 2005 Mar; 5(1):5-21. PubMed ID: 15714261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are drug prices subject to creative destruction? Evidence from the US, 1997-2017.
    Lichtenberg FR
    Health Econ; 2021 Aug; 30(8):1910-1932. PubMed ID: 33987916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and indirect savings from parallel imports in Sweden.
    Granlund D
    Health Econ Rev; 2022 Aug; 12(1):46. PubMed ID: 36044111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceuticals imports in Tanzania: Overview of private sector market size, share, growth and projected trends to 2021.
    Wande DP; Sangeda RZ; Tibalinda P; Mutta IK; Mkumbwa S; Bitegeko A; Kaale E
    PLoS One; 2019; 14(8):e0220701. PubMed ID: 31404109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is medicines parallel trade 'regulatory arbitrage'?
    Costa-Font J
    Int J Health Econ Manag; 2016 Dec; 16(4):321-336. PubMed ID: 27878693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel imports, price controls, and innovation.
    Reisinger M; Saurí L; Zenger H
    J Health Econ; 2019 Jul; 66():163-179. PubMed ID: 31202122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success.
    Mahjoub R; Ødegaard F; Zaric GS
    Health Econ; 2018 Jan; 27(1):e15-e25. PubMed ID: 28627808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International price comparisons for pharmaceuticals. Measurement and policy issues.
    Danzon PM; Kim JD
    Pharmacoeconomics; 1998; 14 Suppl 1():115-28. PubMed ID: 10186473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Constrained competition in parallel drug importation: the case of simvastatin in Germany, the Netherlands, and the United Kingdom].
    Costa-Font J; Kanavos P
    Gac Sanit; 2007; 21(1):53-9. PubMed ID: 17306187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
    Dusetzina SB; Bach PB
    JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.